<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004876</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067536</org_study_id>
    <secondary_id>ICRF-96.084</secondary_id>
    <secondary_id>EU-99018</secondary_id>
    <nct_id>NCT00004876</nct_id>
  </id_info>
  <brief_title>Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer</brief_title>
  <official_title>A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Thalidomide may stop the growth of ovarian cancer by stopping blood
      flow to the tumor.

      PURPOSE: This randomized phase II trial is studying how well giving carboplatin together with
      thalidomide works compared to carboplatin alone in treating patients with ovarian epithelial
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety of carboplatin and thalidomide in patients with stage IC-IV ovarian
           cancer.

        -  Determine the antiangiogenic effect of thalidomide in this patient population.

        -  Compare the efficacy of carboplatin with or without thalidomide in this patient
           population.

      OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.

        -  Arm I: Patients receive carboplatin IV over 1 hour. Treatment continues every 4 weeks
           for up to 6 courses in the absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients receive carboplatin as in arm I. Patients receive thalidomide orally
           once daily. Thalidomide treatment continues for up to 24 weeks commencing on the first
           day of carboplatin therapy and ceasing 4 weeks after the last course of carboplatin.

      PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of angiogenesis</measure>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage IC-IV ovarian epithelial cancer

          -  Post-menopausal OR

          -  Prior bilateral salpingo-oophorectomy and/or total abdominal hysterectomy

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No other concurrent invasive malignancies

          -  Not pregnant

          -  No diabetes mellitus

          -  No chronic neurological disease causing peripheral neuropathy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No other concurrent cytotoxic agents

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Concurrent local radiotherapy for treatment of secondary disease sites allowed

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T.S. Ganesan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Muthuramalingam SR, Braybrooke JP, Blann AD, Madhusudan S, Wilner S, Jenkins A, Han C, Kaur K, Perren T, Ganesan TS. A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. Eur J Gynaecol Oncol. 2011;32(3):253-8.</citation>
    <PMID>21797111</PMID>
  </results_reference>
  <results_reference>
    <citation>Muthuramalingam SR, Braybrooke JP, Madhusudan S, et al.: A randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-303, 86, 2004.</citation>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IC ovarian epithelial cancer</keyword>
  <keyword>stage IIA ovarian epithelial cancer</keyword>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

